• Corpus ID: 34181622

Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.

@article{Birkmayer1989NicotinamidadenindinucleotideT,
  title={Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.},
  author={Walter Prof Dr Birkmayer and G J Birkmayer},
  journal={Annals of clinical and laboratory science},
  year={1989},
  volume={19 1},
  pages={
          38-43
        }
}
The coenzyme Nicotinamidadenindinucleotide (NADH) has been used as novel medication in 34 Parkinson patients in an open label trial. In all patients, a beneficial clinical effect was observed. Twenty-one patients (61.7 percent) showed a very good (better than 30 percent) improvement of disability and 13 patients (38.3 percent) a moderate (up to 30 percent) improvement. The effect of NADH was dependent on the dosage and the severity of the case. The best therapeutic dose was in the range of 25… 
Nicotinamide adenine dinucleotide (NADH) — a new therapeutic approach to Parkinson's disease
The reduced coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 885 parkinsonian patients in an open label trial. About half of the patients received NADH by intravenous
Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
  • J. Birkmayer
  • Medicine
    Annals of clinical and laboratory science
  • 1996
The Coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 17 patients suffering from dementia of the Alzheimer type in an open label trial. In all patients evaluated so
Nicotinamide Adenine Dinucleotide ( NADH )-a New Therapeutic Approach : Preliminary Results With Cancer Patients and Patients With Dementia of the Alzheimer Type
The coenzyme nicotinamide adenine dinucleotide (NADH), also known as Coenzyme I, was used in oral form to treat cancer patients with metastases. In all the 12 cases so far under observation for more
Effects of NADH on dopamine release in rat striatum
TLDR
Results indicate that NADH can increase DA release from striatal slices, although the authors are as yet unable to detect this effect in vivo.
Is NADH Effective in the Treatment of Parkinson’s Disease?
TLDR
Recommendations for the use of reduced nicotinamide adenine dinucleotide in Parkinson’s disease treatment are premature, since NADH indirectly supplies reducing equivalents to the rate-limiting, tyrosine hydroxylase-catalysed step of dopamine synthesis.
Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR).
TLDR
Although systolic BP did not differ between the two groups over the first month, it decreased and stayed markedly lower for the remainder of study in SHR receiving oral NADH, and theoretically could prove to be useful in preventing age-related increases in BP and, thus, various cardiovascular maladies.
A novel treatment target for Parkinson's disease
TLDR
It is hypothesized that GPR109A message and expression are up-regulated in individuals with Parkinson's disease (PD) and predicted that the neuroprotective roles of either niacin or butyrates in CNS occur via GPR 109A.
Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system.
TLDR
It is suggested that NAD(P)H would be unsuitable as a source of reducing equivalents for the bioreductive activation of prodrugs by a reductase enzyme in Antibody Directed Enzyme Prodrug Therapy (ADEPT).
Emerging preclinical pharmacological targets for Parkinson's disease
TLDR
Various emerging preclinical pharmacological targets that may serve as a new promising neuroprotective strategy that could actually help alleviate Parkinson's disease and its symptoms are discussed.
Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH)
TLDR
The experiment shows that NADH is able to increase the activity of the tyrosine hydroxylase and dopamine — production in PC 12 cells up to 6 times.
...
1
2
...

References

SHOWING 1-10 OF 11 REFERENCES
Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution.
TLDR
Intravenously applied iron in the form of a ferri-ferro-complex exhibits a considerable benefit for all patients treated so far, and they regained a remarkable mobility.
CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.
TLDR
TH activity in the caudate nucleus of individuals with both hepatic and diabetic coma were within normal ranges, suggesting a sufficient energy supply of the brain during such metabolic catastrophes, while reduced brain TH activity in patients with hepatic coma who died of acute gastrointestinal bleeding is probably due to severe final cerebral ischemia.
DISTRIBUTION OF TYROSINE HYDROXYLASE IN HUMAN AND ANIMAL BRAIN 1
TLDR
The data suggest that tyrosine hydroxylase may be produced in a soluble form in the cell bodies of the substantia nigra but become bound as it moves toward the nerve endings in the putamen and caudate nucleus.
Iron — a new aid in th e tre a tm en t o f Parkinson patients
  • J. Neur. Trans. 67:287-292,
  • 1986
Biosynthesis and metabolism of tetrathyd robiopterin and m olybdopterin
  • Ann. Rev. Biochem
  • 1985
Die Parkin­ son-Krankheit
  • 1985
m a g u c h i, X , Ra h m a n , K. eta l.: Catecholamine-Related Enzymes and the Biop­ te r in C ofactor in Parkinson’s D isease and Related Extrapyramidal Diseases
  • Adv. Neurol. 40:467-473,
  • 1984
N a m a g u c h i, T., Ka t o , X , S u g im o t o
  • Clin. Chim. Acta 709:305-311,
  • 1981
CNS modulation of adrenal tyrosine hydrox­ ylase in Parkinson’s d isease and m etabolic en cep h a lo p a th ies
  • J. N eur. T rans. S upp l
  • 1978
D istribution of tyrosine hydroxylase in hum an and anim al b ra in
  • J. N eurochem
  • 1971
...
1
2
...